ABVC BioPharma, Inc.
ABVC
$0.742
-$0.1725-18.86%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 500.50K | 136.40K | 25.40K | 152.50K | 739.30K |
| Total Other Revenue | 9.30K | 15.90K | 15.90K | 15.90K | 15.90K |
| Total Revenue | 509.80K | 136.40K | 25.40K | 152.50K | 739.30K |
| Cost of Revenue | 140.00K | 169.30K | 242.10K | 302.00K | 428.20K |
| Gross Profit | 369.90K | -32.80K | -216.70K | -149.60K | 311.00K |
| SG&A Expenses | 6.48M | 8.18M | 8.74M | 7.00M | 7.21M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -16.90K | 10.80K | 10.80K | 10.80K | 10.80K |
| Total Operating Expenses | 6.83M | 8.68M | 9.79M | 8.38M | 10.14M |
| Operating Income | -6.32M | -8.55M | -9.77M | -8.23M | -9.40M |
| Income Before Tax | -8.65M | -11.89M | -12.74M | -10.65M | -11.04M |
| Income Tax Expenses | 64.80K | 63.40K | 256.00K | 256.00K | 1.04M |
| Earnings from Continuing Operations | -8.72 | -11.95 | -12.99 | -10.91 | -12.08 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 474.50K | 577.40K | 369.10K | 394.60K | -187.20K |
| Net Income | -8.24M | -11.37M | -12.62M | -10.52M | -12.27M |
| EBIT | -6.32M | -8.55M | -9.77M | -8.23M | -9.40M |
| EBITDA | -6.29M | -8.52M | -9.74M | -8.20M | -9.37M |
| EPS Basic | -0.97 | -1.78 | -2.37 | -2.52 | -3.52 |
| Normalized Basic EPS | -0.56 | -1.05 | -1.41 | -1.49 | -2.01 |
| EPS Diluted | -0.98 | -1.78 | -2.38 | -2.53 | -3.53 |
| Normalized Diluted EPS | -0.56 | -1.05 | -1.41 | -1.49 | -2.01 |
| Average Basic Shares Outstanding | 40.14M | 31.79M | 23.78M | 17.35M | 13.98M |
| Average Diluted Shares Outstanding | 40.14M | 31.79M | 23.78M | 17.35M | 13.98M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
